Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Matinas Biopharma (MTNB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biodexa Pharmaceuticals American Depositary Shs is the larger company by market cap ($982,950 vs $890,711), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | MTNB |
|---|---|---|
| Share price | $1.88 | $0.7999 |
| Market cap | $982.95K | $890.71K |
| 1-day change | -3.85% | -1.26% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $509.89 | $-17.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-10.35M |
| 52-week high | $357.60 | $14.63 |
| 52-week low | $1.85 | $0.75 |
| Distance from 52-week high | -99.48% | -94.53% |
| Analyst consensus | none | — |
| Avg. price target upside | +375.20% | — |
| Average volume | 618.91K | 80.86K |
| Shares outstanding | 524.24K | 1.11M |
| Employees | 11 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Matinas Biopharma
MTNB stock →Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
BDRX vs MTNB FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Matinas Biopharma?
Biodexa Pharmaceuticals American Depositary Shs (BDRX) is larger, with a market capitalization of $982.95K compared with $890.71K for Matinas Biopharma (MTNB).
Are Biodexa Pharmaceuticals American Depositary Shs and Matinas Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.